Humacyte falls after wider-than-expected quarterly loss
HUMA•Cash position and analyst commentary
Humacyte reported cash, cash equivalents and restricted cash of $80.3 million as of June 30.
BTIG said, "We continue to believe shares can move higher as milestones are achieved and the commercial ramp builds, but acknowledge that near-term revenue visibility remains limited."
As of the last close, the stock was down 35.3% year to date.
Shares fall after Q2 loss and revenue miss
Shares of biotech firm Humacyte (HUMA.O) fell 10% to 63 cents after the company posted a second-quarter loss of 16 cents per share, wider than analysts' estimate for a loss of 1 cent per share, according to LSEG data.
The company reported second-quarter revenue of $406,000, below estimates of $1.12 million.
